Iterion Therapeutics

Iterion Therapeutics company information, Employees & Contact Information

Iterion Therapeutics is a clinical stage biopharmaceutical company focused on developing novel cancer therapeutics. The company's lead product, tegavivint, is a highly specific and potent first-in-class small molecule inhibitor of TBL1 (Transducin Beta-Like Protein 1), a novel downstream target of the canonical Wnt/beta-catenin signaling pathway. Iterion is advancing clinical programs of tegavivint in tumor types with a high prevalence of Wnt/beta-catenin activating mutations, such as hepatocellular carcinoma. In parallel, the company has deep collaborative relationships with leading institutions studying tegavivint in complementary investigator-sponsored trials in acute myeloid leukemia, non small cell lung cancer, pediatric tumors and lymphoma.

Company Details

Employees
16
Founded
-
Address
2450 Holcombe Blvd, Houston,texas,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Houston, Texas
Looking for a particular Iterion Therapeutics employee's phone or email?

Iterion Therapeutics Questions

News

Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings - PR Newswire

Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings PR Newswire

Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments - PR Newswire

Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments PR Newswire

Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpressing Relapsed or Refractory Large B-Cell Lymphomas - PR Newswire

Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpressing Relapsed or Refractory Large B-Cell Lymphomas PR Newswire

Iterion Therapeutics Announces Results from Phase 1 Dose Escalation Study of Tegavivint in Desmoid Tumors to be Presented at the 2022 ASCO Annual Meeting - PR Newswire

Iterion Therapeutics Announces Results from Phase 1 Dose Escalation Study of Tegavivint in Desmoid Tumors to be Presented at the 2022 ASCO Annual Meeting PR Newswire

Iterion Therapeutics Announces Results from Preclinical Study of Tegavivint in Beta-Catenin Mutant Hepatocellular Carcinoma to be Presented at the 34th EORTC-NCI-AACR Symposium 2022 - PR Newswire

Iterion Therapeutics Announces Results from Preclinical Study of Tegavivint in Beta-Catenin Mutant Hepatocellular Carcinoma to be Presented at the 34th EORTC-NCI-AACR Symposium 2022 PR Newswire

Top Iterion Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant